Yahoo
NasdaqGS - Nasdaq Real Time Price USD

AgomAb Therapeutics NV (AGMB)

8.81 -0.28 (-3.08%)
At close: 4:00:01 PM EDT
8.81 0.00 (0.00%)
After hours: 4:00:15 PM EDT
Trade AGMB on Coinbase
Chart Range Bar
Loading chart for AGMB
  • Previous Close 9.09
  • Open 9.05
  • Bid 6.40 x 200
  • Ask 11.22 x 200
  • Day's Range 8.73 - 9.35
  • 52 Week Range 7.97 - 17.82
  • Volume 58,538
  • Avg. Volume 139,223
  • Market Cap (intraday) 433.875M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.08
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 37.67

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

www.agomab.com

62

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/13/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AGMB
40.07%
S&P 500 (^GSPC)
14.02%

1-Year Return

AGMB
40.07%
S&P 500 (^GSPC)
17.29%

3-Year Return

AGMB
40.07%
S&P 500 (^GSPC)
80.36%

5-Year Return

AGMB
40.07%
S&P 500 (^GSPC)
78.87%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings --
Profit Margin 0.00%

Q4

FY25

Q2

FY26

-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

28.00
37.67 Average
8.81 Current
60.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/25/2026
Analyst Piper Sandler
Rating Action Initiated
Rating Overweight
Price Action Announces
Price Target 60

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    524.00M

  • Enterprise Value

    236.85M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.72

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -81.6M

  • Diluted EPS (ttm)

    -2.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    251.98M

  • Total Debt/Equity (mrq)

    0.43%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

8.81 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: